On December 26th, 2023, Henlius filed the Investigational New Drug (IND) for HLX6018 (monoclonal antibody targeting the GARP/TGFβ1 complex) for the treatment of chronic inflammatory diseases in China. As reported by Niklas Zimmer , "Regulatory T cells (Treg) play a critical role in immune homeostasis by suppressing several aspects of the immune response. Herein, Glycoprotein A repetitions predominant (GARP) , the docking receptor for latent transforming growth factor (LTGF-β) , which promotes its activation, plays a crucial role in maintaining Treg mediated immune tolerance . After activation, Treg uniquely express GARP on their surfaces. Due to its location and function, GARP may represent an important target for immunotherapeutic approaches, including the inhibition of Treg suppression in cancer or the enhancement of suppression in autoimmunity. In 2022, Henlius submitted a patent (WO/2022/116877) for an anti-GARP/TGFβ antibody and its method of use. The binding ability wa
China Biotech XYZ Shares News Related to New Drug Development in China